DarioHealth Reports First Quarter 2021 Results and Operational Highlights

·17 min read

Maintained momentum across all three pillars of long term strategic operating plan

Announced acquisition of Upright Technologies, expanding into the musculoskeletal and related pain conditions markets

Generated Q1 revenue growth of 73% over Q4 2020 and 116% over Q1 2020, driven by organic growth and consolidation of Upright Technologies' revenues effective February 2, 2021

GAAP gross margin was 30.1% in the first quarter, excluding acquisition related amortizations Q1 2021 product gross margin nearly doubled to 44.7% as compared to 24.2% in Q4 2020

Ended the first quarter 2021 with cash and cash equivalents of $81.1 million

Company to host conference call and webcast 8:30 am ET tomorrow.

NEW YORK, May 17, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the first quarter of 2021 and provided a corporate and commercial update.

DarioHealth Corp. Logo
DarioHealth Corp. Logo

"During the first quarter, we delivered exceptional financial and operating results, driven by balanced contribution from organic growth and the acquisition of Upright Technologies, which we closed on February 2, 2021," stated Erez Raphael, Chief Executive Officer of Dario. "Our first quarter 2021 revenue of $3.6 million represents growth of 73% sequentially from the fourth quarter of 2020, and 116% year-over-year. Perhaps more importantly, our first quarter revenues, assuming we acquired Upright Technologies as of January 1, 2021, would have been $4.7 million. At the same time, our gross margin percentage, excluding acquisition related amortization, significantly improved to 44.7% of revenues, as compared to 24.2% in Q4 2020. With over $81 million of cash at the end of the first quarter of 2021, we believe that we are well funded to accelerate our growth trajectory.

"Our acquisition of Upright Technologies allows us to address one of the most significant pain points for health care payers – musculoskeletal and related pain conditions. This acquisition is being integrated in our operations and is already generating significant interest from potential customers in need of a novel MSK solution. We will continue to expand into additional chronic conditions supporting our vision of being the most comprehensive digital health solution in the industry. I am pleased with our increasing U.S. sales momentum during the first quarter of 2021. We were especially encouraged by our enrollment, which exceeded 40% and was accomplished at a faster than anticipated rate. We look forward to a very successful year," Mr. Raphael concluded.

"The three pillars of our growth – pivot to Business-to-Business-to-Consumer (B2B2C), transition to a high margin software-as-a-service (SaaS) model, and expansion into additional chronic conditions – are serving us well and are clearly resonating in the marketplace," stated Rick Anderson, President and General Manager of North America. "We launched three accounts during the quarter, including two new employers. Our pipeline currently stands in excess of $700 million and growing especially in our employer market segment. We believe this speaks not only to the breadth and differentiation of our digital health offering, but also to the world-class team and support infrastructure that we have assembled in the U.S."

Q1 2021 and Recent Highlights

  • Announced acquisition of Upright Technologies, expanding into the musculoskeletal and related pain condition markets;

  • Observed first quarter 2021 revenue of approximately $4.7 million, assuming the acquisition of Upright Technologies closed on January 1, 2021;

  • Announced the creation of a virtual clinic focused on diabetes in partnership with MediOrbis and including Dario's Remote Patient Monitoring (RPM) services;

  • Appointed Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships to lead Dario's benefit consultant and alliance outreach as part of the self-insured employers and managed care sales organization;

  • Appointed digital health executive and innovator Chris Chan as Senior Vice President of Employer Sales, to lead growth initiatives in the US self-insured employer market;

  • Selected to be the digital health provider by a self-insured, Fortune 500 subsidiary through Dario's previously announced partnership with Vitality Group; and

  • Published a paper in Journal of Medical Internet Research (JMIR) Diabetes. The paper, "Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study," detailing the results of a clinical study in which increased digital engagement resulted in 43% improvement in blood glucose levels.

First Quarter 2021 Results Summary

Revenues for the first quarter ended March 31, 2021 were $3.6 million, a 73% sequential increase from fourth quarter ended December 31, 2020, and a 116% increase from the $1.7 million in the first quarter ended March 31, 2020.

Revenues generated during the first quarter ended March 31, 2021 were derived mainly from the sales of DarioHealth's products and services and from the consolidated revenues of Upright commencing February 2, 2021.

Gross profit in the first quarter of 2021 was $1,081,000, an increase of $302,000, or 38.8%, compared to gross profit of $779,000 in the first quarter of 2020. Gross profit margin was 30.1% in the first quarter of 2021 as compared to 46.7% in the first quarter of 2020.

Pro-forma gross profit, excluding $526,000 of amortization of expenses related to the acquisition of Upright Technologies, was $1.6 million. Pro forma gross profit margin, excluding amortization of expenses related to the acquisition of Upright Technologies, was 44.7% in the first quarter of 2021, a sequential increase from 24.2% in Q4 2020.

Total operating expenses for the first quarter of 2021 were $15.4 million compared to $10.9 million for the first quarter of 2020, an increase of $4.5 million, or 41.6%. The increase resulted from an increase in our research and development activities, sales and marketing expenses, and from the consolidation of Upright Technologies, partially offset by a reduction in stock-based compensation.

Operating loss for the first quarter of 2021 was $14.3 million, an increase of $4.2 million, or 41.7%, compared to the $10.1 million operating loss in the first quarter of 2020. This increase was mainly due to the increase in our operating expenses.

Net loss was $15.0 million in the first quarter of 2021, an increase of $5.1 million, or 51.3%, compared to the $9.9 million net loss in the first quarter of 2020.

Cash and cash equivalents totaled $81.1 million at March 31, 2021.

Non-GAAP billings for the three months ended March 31, 2021 were $3.69 million, a 116% increase from $1.71 million reported in the three months ended March 31, 2020. The increase is a result of higher sales generated and the consolidation of Upright revenues in the three months ended March 31, 2021 compared to the three months ended March 31, 2020. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

Conference Call Details: Tuesday, May 18, 8:30am ET

Dial-in Number: 877-451-6152

International Dial-in: 201-389-0879

Conference ID: DarioHealth First Quarter 2021 Results Call

Webcast: http://public.viavid.com/index.php?id=144917

Participants are asked to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through June 18, 2021. To listen to the replay, dial 844-512-2921 (domestic) or 412-317-6671 (international) and use replay passcode 13719717. The webcast replay will be available for two months.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, and for more information, visit https://www.dariohealth.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its belief that it is well funded to accelerate its growth trajectory, its intention to continue to expand into additional chronic conditions supporting its vision of being the most comprehensive digital health solution in the industry, its belief that its growing pipeline speaks to the breadth and differentiation of its digital health offering and its world-class team and support infrastructure that it has assembled in the U.S. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Non-GAAP Financial Measures

We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.

Billings (non-GAAP). We define billings as revenue recognized in accordance with GAAP plus the change in deferred revenue from the beginning to the end of the period and adjustment to the deferred revenue balance due to adoption of the new revenue recognition standard less any deferred revenue balances acquired from business combination(s) during the period. We consider billings to be a useful metric for management and investors because billings drive future revenue, which is an important indicator of the health and viability of our business. There are a number of limitations related to the use of billings instead of GAAP revenue. First, billings include amounts that have not yet been recognized as revenue and are impacted by the term of security and support agreements. Second, we may calculate billings in a manner that is different from peer companies that report similar financial measures. Management accounts for these limitations by providing specific information regarding GAAP revenue and evaluating billings together with GAAP revenue.

Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expense provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.

Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, deferred inventory and depreciation of fixed assets. We believe these measures provide useful information to management and investors for analysis of our operating results.




DARIOHEALTH CORP.


CONSOLIDATED BALANCE SHEETS


U.S. dollars in thousands






March 31,


December 31,




2021


2020




Unaudited





ASSETS
















CURRENT ASSETS:








Cash and cash equivalents


$

81,171


$

28,590


Short-term restricted bank deposits



245



187


Trade receivables



468



124


Inventories



5,020



2,293


Other accounts receivable and prepaid expenses



1,352



2,934










Total current assets



88,256



34,128










NON-CURRENT ASSETS:








Deposits



20



20


Operation lease right of use assets



492



498


Long-term assets



138



185


Property and equipment, net



722



576


Intangible assets, net



9,225



-


Goodwill



25,334



-










Total non-current assets



35,931



1,279










Total assets


$

124,187


$

35,407


DARIOHEALTH CORP.


CONSOLIDATED BALANCE SHEETS


U.S. dollars in thousands (except stock and stock data)






March 31,


December 31,




2021


2020




Unaudited




LIABILITIES AND STOCKHOLDERS' EQUITY
















CURRENT LIABILITIES:








Trade payables


$

3,426


$

2,480


Deferred revenues



1,387



1,224


Operating lease liabilities



321



310


Other accounts payable and accrued expenses



6,608



3,020










Total current liabilities



11,742



7,034










OPERATING LEASE LIABILITIES



178



222










STOCKHOLDERS' EQUITY








Common Stock of $0.0001 par value - Authorized: 160,000,000 shares at March 31, 2021 (unaudited) and December 31, 2020; Issued and Outstanding: 15,398,851 and 8,119,493 shares at March 31, 2021 (unaudited) and December 31, 2020, respectively



*) -



*) -


Preferred Stock of $0.0001 par value - Authorized: 5,000,000 shares at March 31, 2021 (unaudited) and December 31, 2020; Issued and Outstanding: 12,400 and 15,823 shares at March 31, 2021 (unaudited) and December 31, 2020, respectively



*) -



*) -


Additional paid-in capital



271,025



171,399


Accumulated deficit



(158,758)



(143,248)










Total stockholders' equity



112,267



28,151










Total liabilities and stockholders' equity


$

124,187


$

35,407


DARIOHEALTH CORP.


CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS


U.S. dollars in thousands (except stock and stock data)






Three months ended




March 31,




2021


2020




Unaudited


Revenues


$

3,595


$

1,667


Cost of revenues



1,988



888


Amortization of acquired intangible assets and inventories step-up



526



-










Gross profit



1,081



779










Operating expenses:








Research and development


$

2,655


$

1,231


Sales and marketing



7,132



4,091


General and administrative



5,621



5,571










Total operating expenses



15,408



10,893










Operating loss



(14,327)



(10,114)










Total financial (income) expenses, net



639



(222)










Net loss


$

(14,966)


$

(9,892)










Deemed dividend


$

544


$

1,275










Net loss attributable to holders of Common Stock


$

(15,510)


$

(11,167)










Net loss per share:
















Basic and diluted net loss per share


$

(0.92)


$

(1.57)


Weighted average number of Common Stock used in computing basic and diluted net loss per share



14,025,921



3,090,790


DARIOHEALTH CORP.


CONSOLIDATED STATEMENTS OF CASH FLOWS


U.S. dollars in thousands






Three months ended




March 31,




2021


2020




Unaudited


Cash flows from operating activities:








Net loss


$

(14,966)


$

(9,892)


Adjustments required to reconcile net loss to net cash used in operating activities:








Stock-based compensation, common stock, and stock instead of cash compensation to directors, employees, consultants, and service providers



4,438



6,356


Depreciation



64



46


Change in operating lease right of use assets



6



80


Amortization of acquired inventories step-up



151



-


Amortization of acquired intangible assets



375



-


Decrease (increase) in trade receivables



318



(102)


Decrease (increase) in other accounts receivable and prepaid expenses and long-term assets



207



(227)


Decrease (increase) in inventories



(32)



193


Decrease in trade payables



(544)



(417)


Decrease in other accounts payable and accrued expenses



(609)



(523)


Increase in deferred revenues



93



42


Change in operating lease liabilities



(33)



(101)










Net cash used in operating activities



(10,532)



(4,545)










Cash flows from investing activities:








Purchase of property and equipment



(68)



(28)


Loans repaid as part of Upright Technologies Ltd. acquisition



(3,016)



-


Cash acquired as part of Upright Technologies Ltd. acquisition



544



-










Net cash used in investing activities



(2,540)



(28)










Cash flows from financing activities:








Proceeds from issuance of common stock, net of issuance costs



64,877



-


Proceeds from exercise of warrants



633



-


Proceeds from exercise of options



201



-










Net cash provided by financing activities



65,711



-










Increase (decrease) in cash, cash equivalents and short-term restricted bank deposits



52,639



(4,573)


Cash, cash equivalents and short-term restricted bank deposits at beginning of period



28,725



20,535










Cash, cash equivalents and short-term restricted bank deposits at end of period


$

81,364


$

15,962


Reconciliation of Revenue to Billing (Non-GAAP)

U.S. dollars in thousands




Three Months Ended

March 31,



2021


2020






GAAP Revenue


3,595


1,667

Add:





Change in deferred revenue


93


42






Billing (Non-GAAP)


3,688


1,709






Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted Operating Loss,

Net Loss and Operating Expenses (Non-GAAP)

U.S. dollars in thousands

Three months ended March 31, 2021



GAAP

Stock-based
compensation
expenses

Amortization of
acquisition
related expenses
and depreciation
of fixed assets

Non-GAAP

Cost of Revenues

$

2,514


(13)


(557)


1,944

Gross Profit


1,081


13


557


1,651










Research and development


2,655


(414)


(15)


2,226

Sales and Marketing


7,132


(1,035)


(11)


6,086

General and Administrative


5,621


(2,976)


(385)


2,260

Total Operating Expenses


15,408


(4,425)


(411)


10,572

Operating Loss

$

(14,327)


4,438


968


(8,921)

Financing income


639


-


-


639

Net Loss

$

(14,966)


4,438


968


(9,560)










Three months ended March 31, 2020



GAAP

Stock-based
compensation
Expenses

Depreciation of
fixed assets

Non-GAAP

Cost of Revenues

$

888


(15)


(29)


844

Gross Profit


779


15


29


823










Research and development


1,231


(337)


(6)


888

Sales and Marketing


4,091


(1,551)


(8)


2,532

General and Administrative


5,571


(4,453)


(3)


1,115

Total Operating Expenses


10,893


(6,341)


(17)


4,535

Operating Loss

$

(10,114)


6,356


46


(3,712)

Financing income


(222)


-


-


(222)

Net Loss

$

(9,892)


6,356


46


(3,490)










Logo - http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
+1-347-767-4220

Media Inquiries:
Investor Relations Contact:
Chuck Padala
chuck@lifesciadvisors.com
+1-646-627-8390

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/dariohealth-reports-first-quarter-2021-results-and-operational-highlights-301292434.html

SOURCE DarioHealth Corp.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting